HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research P...( - Collaborative studies will use His...),Health

- Collaborative studies will use HistoRx AQUA(R)-based assays to evaluate clinical utility of protein biomarkers for predicting treatment response

and outcome in brain tumors -

NEW HAVEN, Conn., Sept. 4 /PRNewswire/ -- HistoRx, Inc., announced today that it has entered into a research collaboration with the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-funded clinical cooperative group. Under the terms of the agreement, HistoRx will provide RTOG researchers access to HistoRx's AQUA(R) technology for biomarker analysis and will develop customized immunohistochemical assays to be used by RTOG in investigating the relationship between specific protein biomarkers and clinical responsiveness in brain tumor patients. HistoRx intends to commercialize assays and reagents developed in the course of the collaboration for clinical use as predictive diagnostics.

The RTOG studies will use a combination of high-throughput tissue microarrays, multiplex analysis, and AQUA(R) analysis-based assays to determine whether brain tumor patients are likely to respond to a specific targeted therapy and whether the biomarkers under investigation may be used to predict survival.

"We selected HistoRx's AQUA(R) technology based on its unique ability to measure protein biomarker expression and localization in diseased tissue sections in a precisely quantitative, reproducible, and standardized way," said Arnab Chakravarti, MD, of Massachusetts General Hospital and a member of the RTOG Translational Research Program. "By eliminating the subjective interpretation inherent in conventional qualitative immunohistochemical analysis, we expect this collaboration will provide a substantial boost to our research in brain cancer by enabling RTOG researchers to reveal stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome."

"As the r
'/>"/>